The-Chuong Trinh

The-Chuong Trinh

Auto-generated profile, based on publicly available information

The-Chuong Trinh

Faculty of Pharmacy, Grenoble Alpes University, La Tronche, 38700, France

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2024 in RSC Advances
Verified
Journal Article
Open access
PDF file
TPTieu-Long Phan
Tieu-Long Phan
TTThe-Chuong Trinh
The-Chuong Trinh
VTVan Thinh To
Van Thinh To
APAn Thanh Pham
An Thanh Pham
CNChung Nguyen
Chung Nguyen
NTNgoc-Tuyen Truong
Ngoc-Tuyen Truong
HIV-1 (human immunodeficiency virus-1) has been causing severe pandemics by attacking the immune system of its host. Left untreated, it can lead to AIDS (acquired immunodeficiency syndrome), where death is inevitable due to opportunistic diseases. Therefore, discovering new antiviral drugs against HIV-1 is crucial. This study aimed to explore a novel machine learning approach to classify compounds that inhibit HIV-1 integrase and screen the dataset of repurposing compounds. The present study had two main stages: selecting the best type of fingerprint or molecular descriptor using the Wilcoxon signed-rank test and building a computational model based on machine learning. In the first stage, we calculated 16 different types of fingerprint or molecular descriptors from the dataset and used each of them as input features for 10 machine-learning models, which were evaluated through cross-validation. Then, a meta-analysis was performed with the Wilcoxon signed-rank test to select the optimal fingerprint or molecular descriptor types. In the second stage, we constructed a model based on the optimal fingerprint or molecular descriptor type. This data followed the machine learning procedure, including data preprocessing, outlier handling, normalization, feature selection, model selection, external validation, and model optimization. In the end, an XGBoost model and RDK7 fingerprint were identified as the most suitable. The model achieved promising results, with an average precision of 0.928 ± 0.027 and an F1-score of 0.848 ± 0.041 in cross-validation. The model achieved an average precision of 0.921 and an F1-score of 0.889 in external validation. Molecular docking was performed and validated by redocking for docking power and retrospective control for screening power, with the AUC metrics being 0.876 and the threshold being identified at −9.71 kcal mol−1. Finally, 44 compounds from DrugBank repurposing data were selected from the QSAR model, then three candidates were identified as potential compounds from molecular docking, and PSI-697 was detected as the most promising molecule, with in vitro experiment being not performed (docking score: −17.14 kcal mol−1, HIV integrase inhibitory probability: 69.81%)

18 October 2023
Verified
Conference Paper
Closed access
TTThe-Chuong Trinh
The-Chuong Trinh
TPTieu-Long Phan
Tieu-Long Phan
VTVan Thinh To
Van Thinh To
GTGia-Bao Truong
Gia-Bao Truong
APAn Thanh Pham
An Thanh Pham
NTNgoc-Tuyen Truong
Ngoc-Tuyen Truong
Anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor, is identified as a crucial target in the progression of anticancer therapeutics for non-small cell lung cancer. This study has executed a Graph Neural Network (GNN) model and compared it with three machine learning (ML) models based on fingerprints for rapid anticancer bioactivity prediction. ALK inhibitors with IC50 values were extracted from the REAXYS database. Following preprocessing, these inhibitors constituted a dataset of 1664 molecules. Subsequently, GNN and ML models were constructed on a training set. The generalizability of these models was assessed by internal and external validation procedures. The graph neural network model yielded promising results, with an average precision of $0.879\pm 0.041$ and an $F1$ score of $0.804\pm 0.049$ in cross-validation. In external validation, the model achieved an average precision of 0.938 and an $F1$ score of 0.863, surpassing the results of the ML models. Therefore, we can infer that the predictive model developed using the GNN is apt for the problem at hand and can be utilized to predict the biological activity of novel ALK inhibitors.

15 September 2025 in Journal of Computer-Aided Molecular Design
Verified
Journal Article
Closed access
PDF file
TTThe-Chuong Trinh
The-Chuong Trinh
TPTieu-Long Phan
Tieu-Long Phan
VTVan Thinh To
Van Thinh To
APAn Thanh Pham
An Thanh Pham
GTGia-Bao Truong
Gia-Bao Truong
NTNgoc-Tuyen Truong
Ngoc-Tuyen Truong

4 September 2024 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
VTVan Thinh To
Van Thinh To
TPTieu-Long Phan
Tieu-Long Phan
BDBao-Vy Ngoc Doan
Bao-Vy Ngoc Doan
CNChung Nguyen
Chung Nguyen
QLQuang-Huy Nguyen Le
Quang-Huy Nguyen Le
NTNgoc-Tuyen Truong
Ngoc-Tuyen Truong
Aims: Immune checkpoint inhibitors targeting PD-L1 are crucial in cancer research for preventing cancer cells from evading the immune system.Materials & methods: This study developed a screening model combining ANN, molecular similarity, and GNINA 1.0 docking to target PD-L1. A database of 2044 substances was compiled from patents.Results: For molecular similarity, the AVALON emerged as the most effective fingerprint, demonstrating an AUC-ROC of 0.963. The ANN model outperformed the Random Forest and Support Vector Classifier in cross-validation and external validation, achieving an average precision of 0.851 and an F1 score of 0.790. GNINA 1.0 was validated through redocking and retrospective control, achieving an AUC of 0.975.Conclusions: From 15235 DrugBank compounds, 22 candidates were shortlisted. Among which (3S)-1-(4-acetylphenyl)-5-oxopyrrolidine-3-carboxylic acid emerged as the most promising.

16 May 2026 in bioRxiv
Verified
Preprint
Open access
TTThe-Chuong Trinh
The-Chuong Trinh
JWJean-Baptiste Woillard
Jean-Baptiste Woillard
GUGuido Uguzzoni
Guido Uguzzoni
CBChristophe Battail
Christophe Battail
Achieving a trade-off between biological utility and patient privacy remains a key challenge for secure data sharing when applying transcriptomic clinical datasets to artificial intelligence in precision oncology. Here, we introduce the first benchmarking study tailored to high-dimensional clinical transcriptomic cancer data, comparing synthetic data generation methods across three clinical cancer trials. Our framework, SynOmicsBench, combines standardized preprocessing with multidimensional evaluation, prioritizing downstream biological validation alongside statistical fidelity and attack-based privacy assessment. Results indicate that no single method dominated all dimensions, with Gaussian Copula achieving the most balanced performance, followed by Avatar, demonstrating that metric-based similarity alone is insufficient to ensure preservation of higher-order molecular dependencies. Synthetic data consistently reproduced biomedical signal directionality but with attenuated effect sizes and inter-replicate variability, supporting hypothesis generation when multi-seed synthesis is adopted. Collectively, this framework provides a reproducible decision-support tool for method selection and promotes biologically informed, privacy-aware adoption of synthetic data in precision oncology.

9 January 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
VTVan Thinh To
Van Thinh To
TPTieu-Long Phan
Tieu-Long Phan
BDBao-Vy Ngoc Doan
Bao-Vy Ngoc Doan
CNChung Nguyen
Chung Nguyen
DNDong-Nghi Hoang Nguyen
Dong-Nghi Hoang Nguyen
NTNgoc-Tuyen Truong
Ngoc-Tuyen Truong
Immune checkpoint inhibitors have garnered significant attention in oncological research over recent years. A plethora of studies have elucidated that inhibitors targeting the Programmed Death-Ligand 1 (PD-L1) play a pivotal role in circumventing the evasion mechanisms of cancer cells against the immune system. This study aimed to develop an integrated screening model combining an Artificial Neural Network (ANN), Molecular Similarity (MS) assessments, and GNINA 1.0 molecular docking, targeting PD-L1 inhibitors. A database of 2044 substances with known PD-L1 inhibitory activity was compiled from Google Patents and used to enhance molecular similarity evaluations and train the machine learning model. For retrospective validation of the docking procedure, the human PD-L1 protein, with the Protein Data Bank (PDB) ID: 5N2F, was employed as a control. In this phase of the study, 15,235 compounds from the DrugBank database were subjected to a series of screening processes: initially through medicinal chemistry filters, followed by MS assessments, the ANN model, and culminating with molecular docking using GNINA 1.0. The decoy generation yielded promising outcomes, evidenced by an AUC-ROC 1NN value of 0.52 and Doppelganger scores with a mean of 0.24 and a maximum of 0.346, indicating a high resemblance of the decoys to the active set. For MS, the AVALON emerged as the most effective fingerprint for similarity searching, demonstrating an Enrichment Factor (EF) of 1% at 10.96%, an AUC-ROC of 0.963, and an optimal similarity threshold of 0.32. The ANN model demonstrated superior performance in cross-validation, achieving an average precision of 0.863±0.032 and an F1 score of 0.745±0.039, outperforming both the Support Vector Classifier (SVC) and Random Forest (RF) models, albeit not significantly. In external validation, the ANN model maintained its superiority with an average precision of 0.851 and an F1 score of 0.790. GNINA 1.0, employed for molecular docking, was validated through redocking and retrospective control, achieving an AUC of 0.975, with a critical cnn_pose_score threshold of 0.73. From the initial 15,235 compounds, 128 were shortlisted using the MS and ANN models. Further screening through GNINA 1.0 identified 22 potential candidates, among which (3S)-1-(4-acetylphenyl)-5-oxopyrrolidine-3-carboxylic acid emerged as the most promising, with a cnn_pose_score of 0.79, a PD-L1 inhibitory probability of 70.5%, and a Tanimoto coefficient of 0.35.